{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:02:40Z","timestamp":1785488560840,"version":"3.56.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1199624"],"award-info":[{"award-number":["OPP1199624"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nigeria ranks fourth globally in human immunodeficiency virus (HIV) prevalence, with an estimated 1.9 million people living with HIV. HIV response in Nigeria has been largely funded by development partners providing free treatment services at designated health facilities. This study aims to examine the benefit incidence of subsidized HIV services and the distribution of benefits across population groups with different socio-economic status (SES).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A survey of patients (n=212) accessing antiretroviral therapy clinics in six purposively selected urban and rural facilities in Enugu State. Principal components analysis was used to create an SES index. The concentration index was used to measure the level of equity in spending across the socio-economic quintiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The majority (60%) of respondents visited facilities every 2\u00a0months. All respondents received HIV drugs for free. The total monthly gross and net benefits of HIV services were US$2143 and US$1755, respectively. Surveyed respondents obtained the largest benefit through using HIV drugs, which accounted for &amp;gt;56% of gross benefit and almost 70% of net benefit of total HIV services. The concentration indices for gross (\u22120.03) and net (\u22120.06) benefits indicate a pro-poor distribution of HIV services.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Subsidized HIV services in Enugu State disproportionately benefited poorer populations, with free HIV drugs constituting the largest share of benefits, indicating equitable access to HIV services in Enugu State.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/inthealth\/ihag063","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:12:52Z","timestamp":1783080772000},"source":"Crossref","is-referenced-by-count":0,"title":["Benefit incidence analysis of HIV services in Enugu State, southeast Nigeria: do the poor preferentially benefit?"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-4148","authenticated-orcid":false,"given":"Ifeyinwa","family":"Arize","sequence":"first","affiliation":[{"name":"Department of Health Administration and Management, Faculty of Health Sciences and Technology, College of Medicine, University of Nigeria Nsukka (Enugu Campus) , Nsukka, Enugu State ,","place":["Nigeria"]},{"name":"Health Policy Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria Nsukka (Enugu Campus) , Nsukka, Enugu State ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9214-7787","authenticated-orcid":false,"given":"Wenhui","family":"Mao","sequence":"additional","affiliation":[{"name":"Center for Policy Impact in Global Health, Duke Global Health Institute, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-8394","authenticated-orcid":false,"given":"Eric","family":"Obikeze","sequence":"additional","affiliation":[{"name":"Department of Health Administration and Management, Faculty of Health Sciences and Technology, College of Medicine, University of Nigeria Nsukka (Enugu Campus) , Nsukka, Enugu State ,","place":["Nigeria"]},{"name":"Health Policy Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria Nsukka (Enugu Campus) , Nsukka, Enugu State ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uchenna","family":"Ezenwaka","sequence":"additional","affiliation":[{"name":"Department of Health Administration and Management, Faculty of Health Sciences and Technology, College of Medicine, University of Nigeria Nsukka (Enugu Campus) , Nsukka, Enugu State ,","place":["Nigeria"]},{"name":"Health Policy Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria Nsukka (Enugu Campus) , Nsukka, Enugu State ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osondu","family":"Ogbuoji","sequence":"additional","affiliation":[{"name":"Center for Policy Impact in Global Health, Duke Global Health Institute, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obinna","family":"Onwujekwe","sequence":"additional","affiliation":[{"name":"Department of Health Administration and Management, Faculty of Health Sciences and Technology, College of Medicine, University of Nigeria Nsukka (Enugu Campus) , Nsukka, Enugu State ,","place":["Nigeria"]},{"name":"Health Policy Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria Nsukka (Enugu Campus) , Nsukka, Enugu State ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2026073104443408300_bib1","doi-asserted-by":"crossref","first-page":"E831","DOI":"10.1016\/S2352-3018(19)30196-1","article-title":"Global, regional, and national incidence, prevalence, and mortality of HIV, 1980\u20132017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017","volume":"6","author":"GBD 2017 HIV Collaborators","year":"2019","journal-title":"Lancet HIV"},{"key":"2026073104443408300_bib2","doi-asserted-by":"crossref","first-page":"E809","DOI":"10.1016\/S2352-3018(19)30230-9","article-title":"The global burden of HIV and prospects for control","volume":"6","author":"Pandey","year":"2019","journal-title":"Lancet HIV"},{"key":"2026073104443408300_bib3","article-title":"UNAIDS 90-90-90: treatment for all","author":"UNAIDS","year":"2019"},{"key":"2026073104443408300_bib4","volume-title":"Revised National HIV and AIDS Strategic Framework 2019\u20132021. Future directions for the HIV\/AIDS response in Nigeria","author":"National Agency for the Control of AIDS","year":"2019"},{"key":"2026073104443408300_bib5","volume-title":"National strategic framework on HIV and AIDS: 2017\u20132021","author":"National Agency for the Control of AIDS","year":"2017"},{"key":"2026073104443408300_bib6","doi-asserted-by":"crossref","first-page":"e0167117","DOI":"10.1371\/journal.pone.0167117","article-title":"What is the economic burden of subsidized HIV\/AIDS treatment services on patients in Nigeria and is this burden catastrophic to households?","volume":"11","author":"Etiaba","year":"2016","journal-title":"PLoS One"},{"key":"2026073104443408300_bib7","article-title":"HIV Financial Dashboard","author":"UNAIDS","year":"2023"},{"key":"2026073104443408300_bib8","volume-title":"National Health Accounts 2017","author":"Federal Ministry of Health","year":"2019"},{"key":"2026073104443408300_bib9","article-title":"Nigeria Demographic and Health Survey 2018 Key Indicators Report","author":"National Population Commission (NPC) [Nigeria], ICF","year":"2019"},{"key":"2026073104443408300_bib10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/heapol\/czac063","article-title":"The impacts of donor transitions on health systems in middle-income countries: a scoping review","volume":"37","author":"Huffstetler","year":"2022","journal-title":"Health Policy Plan"},{"key":"2026073104443408300_bib11","article-title":"health coverage factsheet","volume-title":"Universal","author":"World Health Organization","year":"2019"},{"key":"2026073104443408300_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.healthpol.2008.10.006","article-title":"Examining catastrophic costs and benefit incidence of subsidized antiretroviral treatment (ART) programme in south-east Nigeria","volume":"90","author":"Onwujekwe","year":"2009","journal-title":"Health Policy"},{"key":"2026073104443408300_bib13","doi-asserted-by":"crossref","first-page":"e0152866","DOI":"10.1371\/journal.pone.0152866","article-title":"Equity in health care financing in low- and middle-income countries: a systematic review of evidence from studies using benefit and financing incidence analyses","volume":"11","author":"Asante","year":"2016","journal-title":"PLoS One"},{"key":"2026073104443408300_bib14","volume-title":"Benefit incidence analysis of priority public health services and financing incidence analysis of household payments for healthcare in Enugu and Anambra States, Nigeria","author":"Onwujekwe","year":"2011"},{"key":"2026073104443408300_bib15","article-title":"Do the poor benefit from public spending on healthcare in India? Results from benefit incidence analysis in Tamil Nadu and Orissa","author":"Acharya","year":"2011"},{"key":"2026073104443408300_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12939-019-0921-6","article-title":"Benefit incidence analysis in public health facilities in India: utilization and benefits at the national and state levels","volume":"18","author":"Bowser","year":"2019","journal-title":"Int J Equity Health"},{"key":"2026073104443408300_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1475-9276-11-70","article-title":"Are the poor differentially benefiting from provision of priority public health services? A benefit incidence analysis in Nigeria","volume":"11","author":"Onwujekwe","year":"2012","journal-title":"Int J Equity Health"},{"key":"2026073104443408300_bib18","article-title":"The Global Funds results report 2019","author":"Global Funds","year":"2019"},{"key":"2026073104443408300_bib19","first-page":"115","article-title":"Estimating wealth effects without expenditure data\u2014or tears: an application to educational enrollments in states of India","volume":"38","author":"Filmer","year":"2001","journal-title":"Demography"},{"key":"2026073104443408300_bib20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/heapol\/czq031","article-title":"How to do (or not to do)\u2026a benefit incidence analysis","volume":"26","author":"McIntyre","year":"2011","journal-title":"Health Policy Plan"},{"key":"2026073104443408300_bib21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0167-6296(02)00006-1","article-title":"Inequality aversion, health inequalities and health achievement","volume":"21","author":"Wagstaff","year":"2002","journal-title":"J Health Econ"},{"key":"2026073104443408300_bib22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/tmi.13751","article-title":"Who benefits from tuberculosis outpatient services in Enugu state, Nigeria? A benefit incidence analysis","volume":"27","author":"Ezenwaka","year":"2022","journal-title":"Trop Med Int Health"},{"key":"2026073104443408300_bib23","doi-asserted-by":"crossref","first-page":"e0238720","DOI":"10.1371\/journal.pone.0238720","article-title":"The impact of user fees on uptake of HIV services and adherence to HIV treatment: findings from a large HIV program in Nigeria","volume":"15","author":"Ahonkhai","year":"2020","journal-title":"PLoS One"},{"key":"2026073104443408300_bib24","volume-title":"Poverty and Equity Brief. Nigeria","author":"World Bank","year":"2021"},{"key":"2026073104443408300_bib25","doi-asserted-by":"crossref","first-page":"e2100550","DOI":"10.9745\/GHSP-D-21-00550","article-title":"Sustainability of funding for HIV treatment services: a cross-sectional survey of patients\u2019 willingness to pay for treatment services in Nigeria","volume":"10","author":"Durosinmi-Etti","year":"2022","journal-title":"Glob Health Sci Pract"},{"key":"2026073104443408300_bib26","doi-asserted-by":"crossref","first-page":"1658229","DOI":"10.3389\/fpubh.2025.1658229","article-title":"HIV response financing challenges in sub-Saharan Africa: barriers to achieving the 95-95-95 UNAIDS targets","volume":"13","author":"Kulohoma","year":"2025","journal-title":"Front Public Health"},{"key":"2026073104443408300_bib27","doi-asserted-by":"crossref","first-page":"2325958218774775","DOI":"10.1177\/2325958218774775","article-title":"Drivers of patient costs in accessing HIV\/AIDS services in Tanzania","volume":"17","author":"Mnzava","year":"2018","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2026073104443408300_bib28","article-title":"Impact of US funding cuts on HIV programme in Nigeria","author":"UNAIDS","year":"2025"},{"key":"2026073104443408300_bib29","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S2214-109X(22)00154-1","article-title":"Increasing domestic financing for the HIV\/AIDS response in Nigeria: a catalyst to self-reliance","volume":"10","author":"Nwizu","year":"2022","journal-title":"Lancet Glob Health"}],"container-title":["International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/inthealth\/advance-article-pdf\/doi\/10.1093\/inthealth\/ihag063\/70407255\/ihag063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/inthealth\/advance-article-pdf\/doi\/10.1093\/inthealth\/ihag063\/70407255\/ihag063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:44:41Z","timestamp":1785487481000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/inthealth\/advance-article\/doi\/10.1093\/inthealth\/ihag063\/8748094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1093\/inthealth\/ihag063","relation":{},"ISSN":["1876-3413","1876-3405"],"issn-type":[{"value":"1876-3413","type":"print"},{"value":"1876-3405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"ihag063"}}